Abstract: OBJECTIVE To observe the clinical effect of probiotics Bifidobacterium triple viable capsule on treatment of patients with antibiotic-associated diarrhea so as to better regulate the intestinal function and facilitate the intestinal microecological balance. METHODS A total of 80 patients with antibiotic-associated diarrhea who were treated in the hospital from Jul 2013 to Jul 2015 were enrolled in the study and randomly divided into the observation group and the control group, with 40 cases in each group. The control group was treated with montmorillonite powder, while the observation group was treated with additional Bifidobacterium triple viable capsule on the basis of the treatment with montmorillonite powder. The clinical curative effects, incidence of dysbacteriosis, constituent ratios of pathogens cultured from stool specimens, and incidence of adverse reactions were observed and compared between the two groups of patients. RESULTS The total effective rate of treatment of the observation group was 95.00%, significantly higher than 70.00% of the control group(P＜0.05). The incidence of dysbacteriosis was 0 in the observation group after the treatment, 22.50% in the control group. The constituent ratio of the gram-positive bacteria cultured from the stool specimens was higher in the observation group than in the control group after the treatment, while the constituent ratio of the gram-negative bacteria was lower in the observation group than in the control group (P＜0.05). The obvious adverse reactions occurred in neither group of patients. CONCLUSION The probiotics Bifidobacterium triple viable capsule can achieve significant clinical effect on treatment of the patients with antibiotic-associated diarrhea, regulate the intestinal function, and promote the intestinal microecological balance, with the clinical safety high.